• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    PetMed Express Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    2/10/25 5:12:32 PM ET
    $PETS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $PETS alert in real time by email
    pets-20250210
    0001040130FALSE00010401302025-02-102025-02-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of report (Date of earliest event reported): February 10, 2025
    PetMed Express, Inc.
    (Exact name of registrant as specified in its charter)
    Florida
    000-28827
    65-0680967
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
    420 South Congress Avenue, Delray Beach, Florida 33445
    (Address of principal executive offices) (Zip Code)
    (561) 526-4444
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    o
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    o
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $.001 per share
    PETS
     NASDAQ Global Select Market
    Preferred Stock Purchase RightsN/A
     NASDAQ Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 2.02 Results of Operations and Financial Condition.

    On February 10, 2025, PetMed Express, Inc. (the “Company”) issued a press release announcing its December 31, 2024 third quarter of fiscal year 2025 financial results and other financial information, and that management would review these results in a conference call at 4:30 pm Eastern time on February 10, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
    The information in this Item 2.02 and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such filing.
    The Company is making reference to non-GAAP financial information in both the press release and the conference call. A reconciliation of these non-GAAP financial measures to the nearest comparable GAAP financial measures is contained in the attached press release.
    Item 9.01 Financial Statements and Exhibits.
    (d)Exhibits.
    99.1 – Press release dated February 10, 2025.
    104 – Cover Page Interactive Data File (formatted as Inline XBRL).
    EXHIBIT INDEX
    Exhibit No.
    Description
    99.1
    Press release dated February 10, 2025
    104
    Cover Page Interactive Data File (formatted as Inline XBRL)
    2


    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Dated: February 10, 2025
    PETMED EXPRESS, INC.
    By:/s/ Sandra Y. Campos
    Name:
    Sandra Y. Campos
    Title:
    Chief Executive Officer and President
    3
    Get the next $PETS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PETS

    DatePrice TargetRatingAnalyst
    5/25/2023$20.00Buy
    Lake Street
    1/25/2022$25.00 → $21.00Underweight
    Morgan Stanley
    1/20/2022$32.00Neutral → Buy
    Sidoti
    11/18/2021$25.00Underweight
    Morgan Stanley
    10/1/2021$28.00Hold
    Jefferies
    8/5/2021$22.00Underperform
    Credit Suisse
    More analyst ratings

    $PETS
    SEC Filings

    See more
    • PetMed Express Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PETMED EXPRESS INC (0001040130) (Filer)

      6/16/25 8:37:04 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form NT 10-K filed by PetMed Express Inc.

      NT 10-K - PETMED EXPRESS INC (0001040130) (Filer)

      6/16/25 8:27:28 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PETMED EXPRESS INC (0001040130) (Filer)

      4/9/25 9:24:45 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Wagmo Partners with PetMeds® to Bring Everyday Pet Health Savings to Members

      New partnership gives Wagmo members savings on prescriptions, supplements and everyday pet health essentials Wagmo, the pet healthcare benefit trusted by leading employers, today announced a new partnership with PetMed Express, Inc., parent company of PetMeds and PetCareRx (NASDAQ:PETS). Through this collaboration, Wagmo members now have access to exclusive savings on a wide range of pet health products, ranging from nutritional foods, tasty treats and vet-trusted medications to supplements and daily care essentials for dogs and cats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250624773408/en/ The partnership enhances Wagm

      6/24/25 9:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25

      DELRAY BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) today announced preliminary fourth quarter and fiscal year 2025 results and filed Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission. The Company is unable to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 within the prescribed time period without unreasonable effort or expense. The Company expects to file its Annual Report on Form 10-K with the Securities and Exchange Commission as soon as practicable, and no later than July 1, 2025, in accordance with Rule 12b-25. Preliminary Fourth Quarter

      6/16/25 8:30:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Announces Delay in Fourth Quarter and Fiscal Year End Earnings Release and Conference Call

      DELRAY BEACH, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) today announced it is delaying the release of the Company's fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process. The Company anticipates that it will issue the earnings release, hold the related conference call, and file its Annual Report on Form 10-K as soon as possible, but no later than June 16, 2025. About PetMed Express, Inc. Founded in 1996, PetMeds is a leader in pioneering the digital pet p

      6/10/25 4:05:00 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on PetMed Express with a new price target

      Lake Street initiated coverage of PetMed Express with a rating of Buy and set a new price target of $20.00

      5/25/23 9:17:49 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Morgan Stanley reiterated coverage on PetMed Express with a new price target

      Morgan Stanley reiterated coverage of PetMed Express with a rating of Underweight and set a new price target of $21.00 from $25.00 previously

      1/25/22 10:17:17 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express upgraded by Sidoti with a new price target

      Sidoti upgraded PetMed Express from Neutral to Buy and set a new price target of $32.00

      1/20/22 9:13:56 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Nina Capital Holdings Inc. bought $98,375 worth of shares (25,000 units at $3.94), increasing direct ownership by 0.99% to 2,550,000 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      6/4/25 4:15:58 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Large owner Nina Capital Holdings Inc. bought $96,500 worth of shares (25,000 units at $3.86), increasing direct ownership by 1% to 2,525,000 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      5/23/25 4:15:13 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Large owner Silvercape Investments Ltd bought $29,234 worth of shares (7,401 units at $3.95), increasing direct ownership by 0.32% to 2,307,719 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      5/22/25 10:55:21 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples